Roche P C, Ryan R J, McCormick D J
Department of Laboratory Medicine/Pathology, Mayo Clinic, Rochester, Minnesota 55905.
Endocrinology. 1992 Jul;131(1):268-74. doi: 10.1210/endo.131.1.1612004.
A comprehensive series of overlapping synthetic peptides have been used to study the relationship between the primary structure of the ovarian receptor for LH/human CG (hCG) and hormone binding. Twenty-four consecutive, overlap peptides that replicate the entire extracellular domain of the rat luteal receptor have been synthesized by standard solid-phase techniques on an automated synthesizer. Eight additional peptides from the extracellular domain and three peptides replicating the putative extracellular loop regions have also been synthesized. Each peptide was evaluated in RRAs for interaction with hCG by measuring its ability to competitively inhibit binding of 125I-hCG to membrane receptor. Twelve peptides were found to be potent in RRAs and caused a reduction of half-maximal binding of 125I-hCG at concentrations of 10-250 x 10(-6) M. The 12 active peptides (and adjacent inactive peptides) defined at least 4 independent receptor regions that can interact with hormone. One site near the NH2-terminus was localized to receptor residues Arg21-Pro38. Two more sites of hormone interaction were identified by peptides replicating residues Arg102-Thr115 and Tyr253-Phe272. A fourth binding region was identified in the third putative extracellular loop, replicated by rat luteal receptor peptide Lys573-Lys583. The amino acid sequences of the four active rat LH/hCG receptor regions were aligned and compared with published sequences for other glycoprotein hormone receptors. Three regions (Arg102-Thr115, Tyr253-Phe272, and Lys573-Lys583) showed high sequence homology with the human LH/hCG receptor, human TSH receptor, and rat FSH receptor and may represent contact sites for the alpha-subunit of hormone. The other binding region, Arg21-Pro38 had low sequence homology with the other glycoprotein hormone receptors and is postulated to be a binding determinant for beta-hCG/LH. This report demonstrates that synthetic overlap peptides of confirmed sequence can be used to successively identify hormone interaction sites of glycoprotein hormone receptors.
一系列全面的重叠合成肽已被用于研究促黄体生成素/人绒毛膜促性腺激素(hCG)卵巢受体的一级结构与激素结合之间的关系。通过标准固相技术在自动合成仪上合成了24个连续的重叠肽,这些肽复制了大鼠黄体受体的整个细胞外结构域。还合成了来自细胞外结构域的另外8个肽和3个复制假定细胞外环区域的肽。通过测量每种肽竞争性抑制125I-hCG与膜受体结合的能力,在放射受体分析(RRA)中评估其与hCG的相互作用。发现12个肽在RRA中具有活性,并在10-250×10(-6)M的浓度下使125I-hCG的半数最大结合降低。这12个活性肽(以及相邻的非活性肽)定义了至少4个可与激素相互作用的独立受体区域。靠近氨基末端的一个位点定位于受体残基Arg21-Pro38。通过复制残基Arg102-Thr115和Tyr253-Phe272的肽鉴定出另外两个激素相互作用位点。在第三个假定的细胞外环中鉴定出第四个结合区域,由大鼠黄体受体肽Lys573-Lys583复制。将四个活性大鼠促黄体生成素/hCG受体区域的氨基酸序列进行比对,并与其他糖蛋白激素受体的已发表序列进行比较。三个区域(Arg102-Thr115、Tyr253-Phe272和Lys573-Lys583)与人类促黄体生成素/hCG受体、人类促甲状腺激素受体和大鼠促卵泡激素受体具有高度序列同源性,可能代表激素α亚基的接触位点。另一个结合区域Arg21-Pro38与其他糖蛋白激素受体的序列同源性较低,推测是β-hCG/LH的结合决定因素。本报告表明,已确认序列的合成重叠肽可用于相继鉴定糖蛋白激素受体的激素相互作用位点。